Eikon Therapeutics, Inc. (NASDAQ:EIKN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $24.67.
EIKN has been the topic of several recent research reports. Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. HC Wainwright began coverage on Eikon Therapeutics in a research note on Friday. They issued a “buy” rating and a $23.00 price objective for the company. Wedbush lowered their price target on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a report on Friday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 16th.
Eikon Therapeutics Price Performance
Shares of EIKN opened at $7.42 on Tuesday. The firm has a market capitalization of $401.94 million and a P/E ratio of -1.81. Eikon Therapeutics has a one year low of $6.45 and a one year high of $17.40. The business has a fifty day moving average of $9.41 and a 200 day moving average of $9.93.
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). Analysts expect that Eikon Therapeutics will post -7.24 EPS for the current fiscal year.
Insider Buying and Selling
In related news, major shareholder Group Iv Gp Lp Column acquired 89,200 shares of the stock in a transaction dated Thursday, September 3rd. The stock was acquired at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the purchase, the insider directly owned 89,200 shares of the company’s stock, valued at approximately $1,031,152. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Hedge Funds Weigh In On Eikon Therapeutics
A number of large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in Eikon Therapeutics by 29.0% in the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after purchasing an additional 962,046 shares during the period. State Street Corp bought a new stake in Eikon Therapeutics during the 2nd quarter valued at $4,621,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Eikon Therapeutics in the 2nd quarter worth $3,341,000. Comprehensive Financial Management LLC purchased a new stake in Eikon Therapeutics in the second quarter worth about $1,517,000. Finally, Bank of New York Mellon Corp purchased a new stake in Eikon Therapeutics in the second quarter worth about $624,000.
Eikon Therapeutics Company Profile
Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines using advanced single-molecule imaging, cell biology and computational technologies. Its platform is designed to track the behavior of proteins and other molecular targets in living cells, with the goal of improving the understanding of disease biology and identifying potential drug candidates.
The company is developing a pipeline of therapeutics, including investigational treatments in areas such as oncology and other serious diseases.
Read More
- Five stocks we like better than Eikon Therapeutics
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
